Overview

Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

Status:
Completed

Trial end date:
2016-03-29

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy and safety of ASP0456 in patients with constipation predominant irritable bowel syndrome (IBS-C).

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Linaclotide